Teva Pharma (TEVA) Announces Positive Results from Pridopidine Phase 2 in Huntington Disease
Tweet Send to a Friend
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) announces top-line results from the exploratory Phase 2 PRIDE-HD study. This was a 52-week ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
